Monoclonal Antibodies Update per CDC/IDSA

Monoclonal antibodies (mAbs) against SARS-CoV-2 spike protein show promise in phase 3 clinical trials for the treatment and prevention of COVID-19 Emergency use authorizations (EUAs) for treatment approved for: ambulatory patients with mild to moderate...